These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1164008)

  • 21. Effect of renal failure and dialysis on the serum concentration of the aminoglycoside amikacin.
    Madhavan T; Yaremchuk K; Levin N; Pohlod D; Burch K; Fisher E; Cox F; Quinn EL
    Antimicrob Agents Chemother; 1976 Sep; 10(3):464-6. PubMed ID: 984789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical pharmacokinetics and safety of high doses of ceforanide (BL-S786R) and cefazolin.
    Smyth RD; Pfeffer M; Glick A; Van Harken DR; Hottendorf GH
    Antimicrob Agents Chemother; 1979 Nov; 16(5):615-21. PubMed ID: 526003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of cefamandole in the presence of renal failure in patients undergoing hemodialysis.
    Appel GB; Neu HC; Parry MF; Goldberger MJ; Jacob GB
    Antimicrob Agents Chemother; 1976 Oct; 10(4):623-5. PubMed ID: 984799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of hemodialysis and renal failure on serum and urine concentrations of cephapirin sodium.
    McCloskey RV; Terry EE; McCracken AW; Sweeney MJ; Forland MF
    Antimicrob Agents Chemother; 1972 Feb; 1(2):90-3. PubMed ID: 4680808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of once daily intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients.
    Low CL; Gopalakrishna K; Lye WC
    J Am Soc Nephrol; 2000 Jun; 11(6):1117-1121. PubMed ID: 10820176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics, protein binding, and predicted extravascular distribution of moxalactam in normal and renal failure subjects.
    Peterson LR; Bean B; Fasching CE; Korchik WP; Gerding DN
    Antimicrob Agents Chemother; 1981 Sep; 20(3):378-81. PubMed ID: 6458235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis.
    Lee CS; Peterson JC; Marbury TC
    J Clin Pharmacol; 1983 Jul; 23(7):274-80. PubMed ID: 6886029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical pharmacology phase I of cefazedone, a new cephalosporin, in healthy volunteers. II. Pharmacokinetics in comparison with cefazolin.
    Pabst J; Leopold G; Ungethüm W; Dingeldein E
    Arzneimittelforschung; 1979; 29(2a):437-43. PubMed ID: 582722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of hemodialysis and peritoneal dialysis on aztreonam pharmacokinetics.
    Gerig JS; Bolton ND; Swabb EA; Scheld WM; Bolton WK
    Kidney Int; 1984 Sep; 26(3):308-18. PubMed ID: 6542606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic Study of Cefazolin in Short Daily Hemodialysis.
    Palmer K; Walker S; Richardson R; Jassal SV; Battistella M
    Ann Pharmacother; 2019 Apr; 53(4):348-356. PubMed ID: 30345801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency.
    Humbert G; Leroy A; Fillastre JP; Godin M
    Chemotherapy; 1979; 25(4):189-95. PubMed ID: 456077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Plasma half-life of cefazoline. Study in the normal subject and in the patient with renal insufficiency].
    Humbert G; Fillastre JP; Leroy A
    Nouv Presse Med; 1975 Oct; 4(35):2523-6. PubMed ID: 1196876
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacokinetics of intermittent intravenous cefazolin and tobramycin in patients treated with automated peritoneal dialysis.
    Manley HJ; Bailie GR; Frye R; Hess LD; McGoldrick MD
    J Am Soc Nephrol; 2000 Jul; 11(7):1310-1316. PubMed ID: 10864588
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intraperitoneal cefazolin and ceftazidime during short-dwell exchange in peritoneal dialysis patients with peritonitis.
    Triyawatanyu P; Chariyavilaskul P; Phaisal W; Peerapornratana S; Kanjanabuch T; Praditpornsilpa K; Katavetin P
    Perit Dial Int; 2020 Mar; 40(2):179-184. PubMed ID: 32063189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative pharmacokinetics and clinical experience with a new cephalosporin-derivative: cefazolin.
    Lode H; Gebert S; Hendrischk A
    Chemotherapy; 1975; 21(1):19-32. PubMed ID: 1097207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cefazolin concentrations in bone and synovial fluid.
    Schurman DJ; Hirshman HP; Kajiyama G; Moser K; Burton DS
    J Bone Joint Surg Am; 1978 Apr; 60(3):359-62. PubMed ID: 649639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cefazolin induced seizures in hemodialysis patients.
    Arkaravichien W; Tamungklang J; Arkaravichien T
    J Med Assoc Thai; 2006 Nov; 89(11):1981-3. PubMed ID: 17205885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of hemodialysis on ceftazidime pharmacokinetics.
    Nikolaidis P; Tourkantonis A
    Clin Nephrol; 1985 Sep; 24(3):142-6. PubMed ID: 3899438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cefatrizine (SK&F 60771), a new oral cephalosporin: serum levels and urinary recovery in humans after oral or intramuscular administration--comparative study with cephalexin and cefazolin.
    Actor P; Pitkin DH; Lucyszyn G; Weisbach JA; Bran JL
    Antimicrob Agents Chemother; 1976 May; 9(5):800-3. PubMed ID: 949177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis.
    Bohjanen PR; Johnson MD; Szczech LA; Wray DW; Petros WP; Miller CR; Hicks CB
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2387-92. PubMed ID: 12121909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.